Genetic and epigenetic events that alter gene expression and/or protein function or localization are thought to be the primary mechanism that drives tumorigenesis and governs the clinical behavior of cancers. Yet a number of studies have shown that the effects of oncogene expression or tumor suppressor ablation are highly dependent on cell-type. The molecular basis for this cell-type specificity and how it contributes to tumorigenesis are unknown. Here expression of a truncated SV40 large T-antigen in murine intestinal crypts promoted the formation of numerous adenomatous polyps in the colon and small intestine. In contrast, when the same T-antigen construct is expressed in villous enterocytes the consequences are limited to hyperplasia and dysplasia. The T antigen-induced polyps show high levels of the proto-oncogene c-Myc protein even though there is no transport of β-catenin to the nucleus. Targeting the expression of viral oncogenes to intestinal crypts or villi provides a murine model system for studying cell-type specific effects in tumorigenesis, and is particularly relevant to the study of APC/β-catenin-independent pathways contributing to the generation of intestinal polyps.
INTRODUCTION
The functional unit of the small intestine is composed of crypts, pouch-like structures containing pluripotent stem and progenitor cells, and villi, finger-like projections above the crypts containing differentiated cells and absorbing food nutrients from the lumen. Crypt cells divide regularly, and daughter cells then migrate towards the villi, begin to differentiate and replenish the epithelium. Villi are mainly composed of absorptive cells or enterocytes (95%), with intercalated enteroendocrine and goblet cells, which provide regulatory and secretory functions respectively. Paneth cells, the fourth type of differentiated cells in the small intestine, migrate towards the bottom of the crypts and provide immune and defensive roles (1, 2) .
The study of intestinal tumorigenesis has taken advantage of several mouse models, which recapitulate an/or mimic some or many aspects of the disease (3, 4) . The most widely used models are based on the Apc Min mouse, in which intestinal neoplasia and multiple polyps develop upon mutation of the Apc gene (5) (6) (7) . Despite the central role played by the product of the retinoblastoma gene (RB) in multiple cancers, current models of intestinal tumorigenesis do not address the function of RB in this disease, and the information available is somewhat controversial. For instance, an in vitro system using colorectal cancer cells suggests that RB depletion would prevent proliferation and the formation of colonic tumors by preventing the degradation of β-catenin mediated by E2F1 (8) . In contrast, several reports have indicated that removal of one or more pRb proteins from different intestinal compartments results in ectopic intestinal proliferation and hyperplasia (9) (10) (11) (12) . Finally, studies of a mouse model developed by us and others also suggest a yet uncharacterized role for pRb on intestinal cancer (14) (15) (16) (17) (18) (19) (20) . Expression of the large T antigen from SV40 (SVT) in intestinal enterocytes results in hyperplasia and dysplasia and, in this system, tumorigenic induction and practically all the elicited gene expression changes depend on the ability of SVT to bind and inactivate the pRb pathway.
To test the response of intestinal stem or progenitor cells to SVT we have now used the Villin promoter to initiate expression of SVT and SVT mutants in intestinal crypts.
MATERIALS AND METHODS

Transgenic mice production
Mice expressing SV40 T antigen or the truncation mutant N136 under the control of the rat intestinal fatty acid binding protein promoter (IFABP) have been previously described (15, 21) . The construction of transgenic mice expressing SVT, SVT N136 and SVT E107,108K under the control of the villin promoter was achieved by replacing the IFABP promoter in previously described constructs with a new villin promoter. In particular, regulatory sequences from the mouse villin promoter (the 3.5Kb upstream from the transcription start site) were amplified by PCR with Pfu Ultra II (Stratagene) using specific primers which also added restriction sites C annealing temperature, which generated a 537 bp product in the presence of the transgene. All lines were maintained by crosses to non transgenic FVB mice. All work involving mice was approved by both University of Pittsburgh and Ohio State University Institutional Animal Care and Use Committees and followed NIH guidelines.
Immunohistochemical and apoptosis assays
The mouse intestines were removed from the abdominal cavity, opened along their cephalocaudal axis, and washed with phosphate-buffered saline. Intestine was divided into proximal, middle, distal, colon and cecum sections and "swiss rolls" were prepared and fixed in formalin. Paraffin embedding followed conventional techniques and 5-µm-thick histological sections were subjected to specific antibodies to detect SV40 T antigen (PAb416); c-myc (N262 (sc-764), Santa Cruz); MMP7 (D4H5, Cell Signalling); β-catenin (BD Transduction Labs 610154) and p53 (PAb242). Antigen-antibody complexes were detected with specific 
RESULTS
Generation of transgenic mice expressing a viral oncogene in intestinal crypts
Expression of full length SVT in intestinal crypts appears to be extremely deleterious to the mice, as suggested by our inability to generate founder mice or transgenic progeny expressing consistently the oncogene in crypts (Table I ). In fact, high expression of SVT in murine crypts was only achieved in one founder mouse, which was moribund and had to be sacrificed at 2.7 months. This mouse showed chimeric patches of expression in crypts and villi, and the expression of SVT correlated with an abnormal hyperplastic and dysplastic phenotype, villi branching, areas resembling early polyps and carcinoma ( Fig.   1a-c ). An associated lymphoma and carcinoma also showed partial transgene expression (data not shown), and additional anomalies were observed as well, such as liver hyperplasia and spleen enlargement.
Role of pRb proteins in intestinal tumorigenic induction
The retinoblastoma family of proteins comprises three closely related regulators of the cell cycle, the product of the RB gene (pRb), p107 and p130 (22) . Two SVT proteins, SVT and SVT N136 ( Fig. 1e ) induce intestinal hyperplasia and dysplasia when expressed in enterocytes (19) , and both are able to interfere effectively with the pRb pathway by binding the components via a functional LXCXE motif (Fig. 1e) (Table I ). Strong nuclear expression of the corresponding protein was detected from the bottom of the crypts all the way to the top of the villi along the intestinal axis (Fig.1c) , confirming that the Villin promoter efficiently directs the expression of the transgene to the intestinal crypts, and subsequently to enterocytes. The SVT E107,108K -expressing mice developed and survived normally, had no indications of an abnormal intestinal phenotype (Fig.1d) and showed no tumorigenesis.
In contrast, we generated 7 transgenic founders expressing the truncated SVT N136 oncogene, which retains the ability to disrupt the pRb pathway but is unable to interact with p53 ( Fig. 1e ). All of these founders presented a chimeric phenotype, and only some portions of the intestine showed expression of the transgene (Fig. 2b,d , Table I ). The percentage of chimerism varied between founders, but transgene expression always extended from the bottom of the crypts to the tips of the villi (Fig. 2b) , and higher SVT N136 levels correlated with a more evident abnormal phenotype. Transgene expression was present both in the nuclei and cytoplasm (Fig. 2d) , as expected from a small protein product able to pass freely through the nuclear pores. very limited number of positive and very sick progeny (two pups) which died prior to analysis. A summary of the results is shown in Table I .
Role of p53 and p53-dependent apoptosis in intestinal tumorigenesis
One of the main controllers of tumorigenesis is the cellular p53 tumor suppressor, which plays roles in DNA repair, cell cycle progression and apoptosis. Disruption of the pRb pathway and other stimuli in normal cells triggers a p53-response aimed to avert abnormal proliferation. SVT is able to counteract the p53 response by directly binding, stabilizing and inhibiting p53, therefore preventing growth arrest or apoptosis and contributing to abnormal cell proliferation.
In the small intestine, we have previously shown that the expression SVT and SVT-mutants in enterocytes does not result in upregulation or disruption of p53 and p53-target genes (16, 19) , and disruption of the p53 pathway is not required to induce intestinal tumorigenesis in this transgenic system (16) . However, apoptosis and p53 are absent in normal intestines but, unlike in villi cells, gamma radiation triggers a robust p53 response in normal crypt cells (23) .
This suggests that expression of SVT and SVT mutants in crypts might affect p53 in a cellspecific manner, and prompted us to examine the levels of p53 and apoptosis in Villin-driven SVT-expressing transgenic mice. As described above, intestinal polyps were present following expression of SVT N136 in crypts, but not in villi (Fig.1) , and we observed that, in crypts, expression of SVT N136 sufficed to increase the levels of apoptosis (Fig. 3a, b) .
Apoptosis was restricted to the areas of SVT N136 expression, but was absent in normal, nonexpressing areas. Expression of SVT N136 -which lacks a functional p53-binding domain-in crypts did not raise the levels of p53 significantly (Fig. 3d) , either in areas expressing the transgene or those lacking it (Fig. 3c) . In sharp contrast, expression in the crypts of SVT levels of p53 considerably (Fig. 3f and data not shown) . In this case, upregulation ofpresumably inactive-p53 was found in a large subset of cells expressing the transgene, including the intestinal crypts and tumors present in the SVT founder (Fig. 3e,f and data not shown).
Molecular characterization of SVT
N136 -induced intestinal polyps
We then investigated the properties of intestinal polyps in SVT (Fig. 4a) . In contrast, normal nuclear localization of β-catenin in crypt cells was present in all cases (Fig. 4b) .
We then monitored the expression of c-myc, a target of β-catenin frequently amplified and/or overexpressed in premalignant and malignant stages of human colorectal carcinomas (31, 32) , but whose expression remains restricted to the crypt compartment in normal intestinal epithelium (33) . Despite the absence of nuclear β-catenin in abnormal areas, we found that (Fig. 4c,f) . Furthermore, the expression of MMP7 (Figure 4e 
DISCUSSION
We have developed a model system to induce intestinal tumorigenesis that relies on the expression of a potent oncogene, the large T antigen from SV40 (SVT), in different compartments within the intestinal epithelium. We have previously shown that the expression of SVT in the differentiated cells of the villi induces hyperplasia and dysplasia, but tumorigenesis does not proceed further under those conditions (16) . Although the major cellular targets of SVT are the tumor suppressor p53 and the pRb proteins (pRb, p107 and p130), SVT induction of intestinal tumorigenesis in the villi is completely dependent on the disruption of the pRB pathway (17-19) but does not require p53 inactivation (16) . SVT interferes with all three pRb proteins, therefore our results are consistent with those of other authors suggesting that the ablation of at least two members of the pRb family (pRb/p130 or pRb/p107) is required to induce ectopic proliferation in the villi (9) . In contrast, we and others have shown that removal of pRb from the crypt pluripotent progenitor cells is sufficient for enterocyte proliferation (10-12).
We thus aimed to understand if tumorigenic induction is dependent on which cell type the oncogene -or other alteration-is first expressed, and have generated transgenic mice that express different viral oncogenes first in intestinal crypts, and subsequently in the resulting villi.
We found that the expression of SVT in intestinal crypts appears to be extremely deleterious to the mice. In contrast, mice expressing a mutant T antigen unable to disrupt the pRb pathway (SVT Based on our previous results (11), plus those presented in this manuscript, we propose a model to explain how Rb affects intestinal proliferation (Fig 5) : The E2F activators E2F1-2-3 contribute to maintain proliferation in the crypts by activating specific promoters. As crypt cells migrate up the villi, activation of the E2F target genes is initially prevented by the binding of underphosphorylated pRb to E2F1-2-3. Final growth arrest in the villi is achieved by active repression of the promoters via p130/E2F4 (21) as part of the DREAM complex (35) . In agreement with this model, cell cycle re-entry in the villi requires the loss of multiple Rb family members (9) , and disruption of all pRb proteins by SVT or SVT N136 bypasses growth restriction, allowing E2F activators to drive gene expression and induce ectopic proliferation (14, 15, 19, 21) . Also in agreement with this model, expression of SVT mutants unable to disrupt the pRb pathway in the villi does not induce intestinal proliferation nor upregulation of E2F target genes (17) (18) (19) , and expression in the crypts fails to induce tumorigenesis (this manuscript).
We next examined the levels of p53 and apoptosis in mice expressing SVT in intestinal to induce hyperplasia and dysplasia (16) . However, and unlike enterocytes that do not show increased p53 levels or activity in response to DNA damage or T antigen expression, normal crypt progenitor cells exhibit a robust p53 response following gamma radiation (23) . We thus postulated that expression of SVT and SVT mutants in crypts might affect p53 in a cell-specific manner.
We found that crypt expression of SVT N136 -which disrupts the pRb pathway but lacks a functional p53-binding domain-sufficed to increase the levels of apoptosis, which was restricted to the areas of transgene expression. However this expression did not raise the levels of p53 significantly, suggesting that either apoptosis was not mediated by p53 or that the levels of p53 were insufficient to allow for immunohistochemical detection. We 
catenin.
Other pathways, such as rapid protein degradation, can control c-myc independently of β-catenin nuclear localization (39) . One possibility is that SVT 
